COMPANIES When AstraZeneca revealed details last week of 3,500 job cuts across its global research and development operations, it was not just the company’s own employees who felt concerned.
The decision by the Anglo-Swedish pharmaceuticals group is the latest in a series of recent restructurings that will have an important impact on the volume of future medical innovation and the way in which it takes place.
